-+ 0.00%
-+ 0.00%
-+ 0.00%
Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
Share
Listen to the news

SHANGHAI and NANTONG, China, Nov. 2, 2026 /PRNewswire/ -- Ractigen Therapeutics, a leading clinical-stage biopharmaceutical company developing innovative small activating RNA (saRNA) therapeutics, today announced the official initiation of its multi-center Phase II clinical trial (Study RAG010201) of RAG-01 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) in China, marked by a clinical site initiation meeting held at Fudan University Shanghai Cancer Center (FUSCC).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending